# Evaluating Treatment Outcomes Using Darolutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer.

> **NCT06660862** · PHASE4 · NOT_YET_RECRUITING · sponsor: **University of Chicago** · enrollment: 80 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Darolutamide
- **DRUG:** Physician choice Androgen Deprivation (Hormone) Therapy

## Key facts

- **NCT ID:** NCT06660862
- **Lead sponsor:** University of Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-11
- **Primary completion:** 2029-11
- **Final completion:** 2029-11
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06660862

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06660862, "Evaluating Treatment Outcomes Using Darolutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06660862. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*